What we do

At Polpharma Biologics we are focused on developing the next generation of biosimilars to improve patient access and reduce health care costs.
Our pipeline is continuously growing and our late stage products are nearing the market. We look to partner with some of the worlds largest biotech so our biosimilars can reach those that need them.

Our biosimilar pipeline
icon 8

biologics in the pipeline

icon 3

sites

icon >10 000l

Bioreactor capacity

icon Over 800

People employed

icon Over 50

Polish scientists returned from abroad

icon We care

our driving value for what we do

About biosimilars

Biosimilars are biotherapeutics that have very similar properties to an existing, approved therapeutic. Unlike generics they are not identical to the originator product due to natural variability and the complex nature of biological medicines.

However through clinical trials they are shown to be equally as safe and effective as the originator and go through a rigourous approval process. The use of biosimilars can significantly reduce health care costs and improve patients access.

Our science and technology

We have some of the most advanced development and manufacturing facilities in Europe staffed by highly skilled and experienced scientists from across the globe.

Technical Development

Our cell line development, process development and analytical development team set the foundation for all our programs. They are the first step in creating our pipeline.

Learn more
Manufacturing

We have state of the art manufacturing facilities for both mammalian and microbial manufacturing for clinical for preclinical, clinical and commercial supply, including fill and finish.

Learn more
Clinical

Our clinical operations group manages pre-clinical and clinical trials, a lengthy process but critical to ensuring our biosimilars are safe and effective for the patients that need them most.

Learn more

Let’s collaborate and deliver quality biosimilars together.

Get in touch for more information.